Chantasrisawad Napaporn, Jantarabenjakul Watsamon, Anugulruengkitt Suvaporn, Punrin Suda, Limsuwun Kornvika, Sawangsinth Panadda, Phasomsap Chayapa, Sophonphan Jiratchaya, Pancharoen Chitsanu, Puthanakit Thanyawee
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Thai Red Cross Emerging Infectious Diseases Clinical Center (TRC-EID), King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Int J Infect Dis. 2021 Nov;112:89-95. doi: 10.1016/j.ijid.2021.09.025. Epub 2021 Sep 20.
The World Health Organization recommends a 2-dose rabies pre-exposure prophylaxis (PrEP) regimen. This study aimed to compare the immunogenicity of rabies PrEP regimens co-administered with inactivated quadrivalent influenza vaccine (IIV4).
Children aged 3 to 9 years were randomly assigned (2:2:1) to receive 0.25 mL of chromatographically purified Vero cell rabies vaccine intramuscularly: Group A at day 0, 7 with IIV4; Group B at day 0, 28 with IIV4; Group C at day 0, 7. A booster-dose of CPRV was given on day 365. Primary outcome was the proportion of children with protective rabies virus neutralizing antibody (RVNA) ≥ 0.5 IU/mL, on day 42 and 7 days post-booster.
From November 2019 to January 2020; 100 children with a median age (IQR) of 5.4 years (4.8-7.3) were enrolled. All participants achieved protective RVNA titers on day 42 and 7-days post booster. Geometric mean titers (GMT) at day 42 were Group A, 8.98(95%CI 7.06-11.42); Group B, 23.89(95%CI 19.33-29.51); Group C, 9.94(95%CI 7.03-14.06). Likewise, RVNA GMT at 7 days post-booster were Group A, 42.53(95%CI 18.41-66.64); Group B, 23.19(95%CI 17.28-29.10); Group C, 57.75 (95%CI 35.86-79.67).
The 2-dose PrEP regimen of rabies vaccine produces adequate immune response either 0,7 or 0, 28 regimens.
世界卫生组织推荐采用2剂次狂犬病暴露前预防（PrEP）方案。本研究旨在比较狂犬病PrEP方案与四价流感灭活疫苗（IIV4）联合接种时的免疫原性。
将3至9岁儿童随机分组（2:2:1），肌肉注射0.25 mL经层析纯化的Vero细胞狂犬病疫苗：A组在第0、7天接种IIV4；B组在第0、28天接种IIV4；C组在第0、7天接种。在第365天给予一剂狂犬病疫苗加强针。主要结局是在第42天和加强针接种后7天时狂犬病病毒中和抗体（RVNA）≥0.5 IU/mL的儿童比例。
2019年11月至2020年1月；纳入100名儿童，中位年龄（IQR）为5.4岁（4.8 - 7.3）。所有参与者在第42天和加强针接种后7天时均达到保护性RVNA滴度。第42天时的几何平均滴度（GMT）：A组为8.98（95%CI 7.06 - 11.42）；B组为23.89（95%CI 19.33 - 29.51）；C组为9.94（95%CI 7.03 - 14.06）。同样，加强针接种后7天时的RVNA GMT：A组为42.53（95%CI 18.41 - 66.64）；B组为23.19（95%CI 17.28 - 29.10）；C组为57.75（95%CI 35.86 - 79.67）。
狂犬病疫苗2剂次PrEP方案无论是0、7方案还是0、28方案均能产生足够的免疫反应。
